


(E/Z)-GSK-3β inhibitor 1

Cat. No.:	HY-126144A
CAS No.:	3367-88-2
Molecular Formula:	C ₁₄ H ₁₀ N ₂ O
Molecular Weight:	222.24
Target:	GSK-3
Pathway:	PI3K/Akt/mTOR; Stem Cell/Wnt
Storage:	-20°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 50 mg/mL (224.98 mM; Need ultrasonic)
H₂O : < 0.1 mg/mL (insoluble)

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	4.4996 mL	22.4982 mL	44.9964 mL
	5 mM	0.8999 mL	4.4996 mL	8.9993 mL
	10 mM	0.4500 mL	2.2498 mL	4.4996 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: 2.5 mg/mL (11.25 mM); Suspended solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description

(E/Z)-GSK-3β inhibitor 1 is a racemic compound of (E)-GSK-3β inhibitor 1 and (Z)-GSK-3β inhibitor 1 isomers. GSK-3β inhibitor 1 (compound 3a) is a glycogen synthase kinase 3β (GSK-3β) inhibitor and demonstrates high antidiabetic efficacy, with an IC₅₀ of 4.9 nM^[1].

REFERENCES

[1]. Lozinskaya NA, et al. Synthesis and biological evaluation of 3-substituted 2-oxindole derivatives as new glycogen synthase kinase 3β inhibitors. *Bioorg Med Chem.* 2019 May 1;27(9):1804-1817.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA